Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Biosimilar Monoclonal Antibodies Market Restraints, Opportunities, and Threats
#1
The global biosimilar monoclonal antibodies market is projected to reach a value of over US$ 32,000.0 Mn in 2028 at a CAGR of 35.7% over the forecast period. The report offers in-depth insights, revenue details, and other vital information regarding the global biosimilar monoclonal antibodies market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2028.

Major factor driving growth of the global biosimilar monoclonal antibodies market is patent expiry on essential biological drugs. These patent expiries allow manufacturers to produce biosimilar drugs in bulk quantities and offer it to the general public at much cost-effective rates. 

Also, a number of pipeline products and increasing cases of chronic and autoimmune diseases are other factors expected to fuel growth of the global biosimilar monoclonal antibodies market over the forecast period. 

PDF report and online dashboard will help you understand:
1. Competitive benchmarking
2. Market forecasts
3. Company market shares
4. Market opportunities
5. Latest trends & dynamics


Get sample report PDF: https://marketresearch.biz/report/biosimilar-monoclonal-antibodies-market/request-sample/

Revenue from the others segment is anticipated to grow moderately over the forecast period, and is projected to register a CAGR of around 30.0% over the forecast period.

The global biosimilar monoclonal antibodies market was valued at US$ 1,516.9 Mn in 2016 and is projected to reach US$ 32,015.0 Mn in 2026 at a CAGR of 35.7% from 2017 to 2026. The Adalimumab drug class segment is estimated to account for the major revenue share of 29.1% by end of 2017, owing to its cost-effectiveness and capability to cure oncological diseases, Crohn’s colitis disease, and spondylitis.
Reply


Forum Jump:


Users browsing this thread: 1 Guest(s)